NEW YORK (GenomeWeb) – Genedrive announced today that it has signed a distribution agreement with Arkray Healthcare for its Genedrive HCV ID kit and platform for use in India.
As part of the agreement, Genedrive will maintain responsibility for product development, quality management, and manufacturing, while Arkray will be in charge of sales, marketing, customer support, and distribution activities across India. The partners will work together to acquire the required regulatory approvals in India for the Genedrive HCV ID kit.
Genedrive HCV is a qualitative assay for hepatitis C virus RNA. It runs on the Genedrive PCR platform, and provides results directly from plasma samples without a separate viral RNA extraction step.
"This agreement provides access to another important and very relevant region region for Genedrive," Genedrive CEO David Budd said in a statement.
Genedrive anticipates commercial activities to begin during the second half of 2018.
Genedrive previously signed a distribution agreement with Sysmex for its Genedrive HCV ID kit and PCR platform in the Asia Pacific region in November.
In February, Genedrive was awarded an £1.1 million ($1.5 million) grant from Innovate UK to further develop its assay system for tuberculosis and rifampin resistance.